Literature DB >> 10718858

The challenge procedure influences the extent of allergen-induced urinary excretion of leukotriene E4.

M Kumlin1, B Dahlén.   

Abstract

BACKGROUND: Cysteinyl-leukotrienes are central mediators in asthma and urinary leukotriene E4 (LTE4) is a reliable marker of their endogenous formation.
OBJECTIVE: This study tested the hypothesis that the procedure used for allergen bronchoprovocation influences the bronchoconstrictor response and the amount of LTE4 excreted following allergen challenge.
METHODS: Seven atopic asthmatic men underwent two allergen bronchoprovocations 4 weeks apart. The same total dose of allergen was given at both sessions, cumulatively on one occasion and as a single dose at the other session. Urine was collected in hourly samples before and after challenge and LTE4 was measured with previously validated methodology.
RESULTS: The mean (+/- SE) drop in FEV1 was not significantly different between the cumulative (29 +/- 2.4%) and the single dose challenge (25 +/- 2.8%). There was a significant increase in post-challenge levels of urinary LTE4 after both sessions. The peak excretion of LTE4 occurred 1 h following the maximal drop in FEV1 for both challenges. However, the post-challenge increase in urinary LTE4 was significantly larger at the cumulative session. In fact, the net increase (post-challenge minus prechallenge) of urinary LTE4 was more than twofold higher after the cumulative session (AUC 0-3 h post-challenge: 46.7 +/- 8.2 vs 22.1 +/- 9.8, P < 0.05).
CONCLUSION: The peak excretion of urinary LTE4 occurred within 2 h after the termination of either challenge but the magnitude of urinary excretion of LTE4 was larger when cumulative challenge was performed. The findings are important to consider when designing studies where allergen-induced urinary excretion of LTE4 is an outcome variable.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10718858     DOI: 10.1046/j.1365-2222.2000.00738.x

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  3 in total

1.  Increase in urinary leukotriene LTE4 levels in acute asthma: correlation with airflow limitation.

Authors:  S A Green; M-P Malice; W Tanaka; C A Tozzi; T F Reiss
Journal:  Thorax       Date:  2004-02       Impact factor: 9.139

2.  Plasma 9alpha,11beta-PGF2, a PGD2 metabolite, as a sensitive marker of mast cell activation by allergen in bronchial asthma.

Authors:  G Bochenek; E Nizankowska; A Gielicz; M Swierczyńska; A Szczeklik
Journal:  Thorax       Date:  2004-06       Impact factor: 9.139

Review 3.  Allergen provocation tests in respiratory research: building on 50 years of experience.

Authors:  Gail M Gauvreau; Beth E Davis; Guy Scadding; Louis-Philippe Boulet; Leif Bjermer; Adam Chaker; Donald W Cockcroft; Barbro Dahlén; Wyste Fokkens; Peter Hellings; Nikolaos Lazarinis; Paul M O'Byrne; Ellen Tufvesson; Santiago Quirce; Maurits Van Maaren; Frans H de Jongh; Zuzana Diamant
Journal:  Eur Respir J       Date:  2022-08-25       Impact factor: 33.795

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.